Figure 5 — Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients

Research Paper|Volume 15, Issue 11|pp. 5066–5074

Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients

Back to articleFigure 5(5 of 5)

100%

Figure 5.Multivariate regression analysis of prognostic factors for EGFR-mutated non-small cell lung cancer patients receiving TKI therapy in the propensity-matched cohort. (A) Progression-free survival. (B) Overall survival. EGFR: Epidermal growth factor receptor. TKI: tyrosine kinase inhibitor. ECOG: Eastern Cooperative Oncology Group.